A Complex Adaptive Health System: Real-World Examples

2017 ◽  
pp. 111-124
Author(s):  
Joachim P. Sturmberg
2012 ◽  
pp. 1316-1327
Author(s):  
Matthieu J. Guitton

The real world impacts the use of the cyber world. Two characteristics shape the Canadian cyber world: first, the bilingual nature of Canada; second and most important, the immensity of the Canadian territory and the related difficulties in physically reaching its population. Due to this situation, Canada has been at the edge of the development of cyberspace, investing major efforts in cyber-applications for the health system and for tele-education. This chapter describes the characteristics of cyber behavior in Canada and summarizes the current state of Canadian cyberspace, with a particular focus on the involvement of the government, media and entertainment, universities and hospitals, and a special emphasis on tele-medicine. Finally, this chapter describes some of the research of Canadian scientists in the field of cyber behavior. In the context of a globalized world, the experience of Canada provides a useful example for optimizing the use of cyberspaces in large territories, and facilitating interactions between different – real or virtual – communities.


2019 ◽  
Vol 14 (4) ◽  
pp. 490-500 ◽  
Author(s):  
Nadia Pillai ◽  
Judith E Lupatsch ◽  
Mark Dusheiko ◽  
Matthias Schwenkglenks ◽  
Michel Maillard ◽  
...  

Abstract Background and Aims We evaluated the cost-effectiveness of early [≤2 years after diagnosis] compared with late or no biologic initiation [starting biologics >2 years after diagnosis or no biologic use] for adults with Crohn’s disease in Switzerland. Methods We developed a Markov cohort model over the patient’s lifetime, from the health system and societal perspectives. Transition probabilities, quality of life, and costs were estimated using real-world data. Propensity score matching was used to ensure comparability between patients in the early [intervention] and late/no [comparator] biologic initiation strategies. The incremental cost-effectiveness ratio [ICER] per quality-adjusted life year [QALY] gained is reported in Swiss francs [CHF]. Sensitivity and scenario analyses were performed. Results Total costs and QALYs were higher for the intervention [CHF384 607; 16.84 QALYs] compared with the comparator [CHF340 800; 16.75 QALYs] strategy, resulting in high ICERs [health system: CHF887 450 per QALY; societal: CHF449 130 per QALY]. In probabilistic sensitivity analysis, assuming a threshold of CHF100 000 per QALY, the probability that the intervention strategy was cost-effective was 0.1 and 0.25 from the health system and societal perspectives, respectively. In addition, ICERs improved when we assumed a 30% reduction in biologic prices [health system: CHF134 502 per QALY; societal: intervention dominant]. Conclusions Early biologic use was not cost-effective, considering a threshold of CHF100 000 per QALY compared with late/no biologic use. However, early identification of patients likely to need biologics and future drug price reductions through increased availability of biosimilars may improve the cost-effectiveness of an early treatment approach.


2011 ◽  
Vol 14 (7) ◽  
pp. A438
Author(s):  
O. Clark ◽  
L.G.O. Clark ◽  
T.E.A. Botrel ◽  
B. Rosa ◽  
P. Medina ◽  
...  

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e17041-e17041
Author(s):  
M. Ulcickas Yood ◽  
P. Feng Wang ◽  
S. Hensley Alford ◽  
S. Oliveria ◽  
K. Wells ◽  
...  

e17041 Background: Although treatment effects and toxicities have been reported from randomized clinical trials of patients with squamous cell carcinoma of the head and neck (SCCHN), little information is available from real-world clinical practice where heterogeneous treatment patterns and patient populations may lead to different estimates than those observed in clinical trials. Methods: Using a population-based tumor registry at a large, Midwestern integrated health system, we identified all cases of stage III or IV SCCHN diagnosed 2000–2006. The incidence/severity of acute and late toxicities associated with SCCHN treatment was obtained from detailed medical record review of health system encounters, including physician notes. Grading of toxicities (using CTCAE3 criteria), distinction between acute and late toxicity, and analyses by treatment are ongoing. The incidence and severity of toxicities will be presented by treatment regimen, tumor location and tumor stage. We presented here an interim analysis. Results: Among the target population of 194 patients that will ultimately be included in this study, 137 medical record reviews have been completed to date. The percentages of patients with toxicities, including 95% confidence intervals are presented in the table , below. Conclusions: Toxicity in patients with advanced SCCHN is common. Data from clinical practice quantifying the incidence are lacking, these data from an observational real-world study provide important baseline information on the incidence of toxicities in patients with advanced SCCHN and also call for safer effective treatment for SCCHN. [Table: see text] [Table: see text]


2012 ◽  
Vol 15 (7) ◽  
pp. A364
Author(s):  
R. Romanelli ◽  
A. Leahy ◽  
T. Jukes ◽  
X. Ye ◽  
A. Luan ◽  
...  

2020 ◽  
Author(s):  
Hassane Alami ◽  
Pascale Lehoux ◽  
Yannick Auclair ◽  
Michèle de Guise ◽  
Marie-Pierre Gagnon ◽  
...  

UNSTRUCTURED Artificial intelligence (AI) is seen as a strategic lever to improve access, quality, and efficiency of care and services and to build learning and value-based health systems. Many studies have examined the technical performance of AI within an experimental context. These studies provide limited insights into the issues that its use in a real-world context of care and services raises. To help decision makers address these issues in a systemic and holistic manner, this viewpoint paper relies on the health technology assessment core model to contrast the expectations of the health sector toward the use of AI with the risks that should be mitigated for its responsible deployment. The analysis adopts the perspective of payers (ie, health system organizations and agencies) because of their central role in regulating, financing, and reimbursing novel technologies. This paper suggests that AI-based systems should be seen as a health system transformation lever, rather than a discrete set of technological devices. Their use could bring significant changes and impacts at several levels: technological, clinical, human and cognitive (patient and clinician), professional and organizational, economic, legal, and ethical. The assessment of AI’s value proposition should thus go beyond technical performance and cost logic by performing a holistic analysis of its value in a real-world context of care and services. To guide AI development, generate knowledge, and draw lessons that can be translated into action, the right political, regulatory, organizational, clinical, and technological conditions for innovation should be created as a first step.


Sign in / Sign up

Export Citation Format

Share Document